Thrombosis Drugs Market - By Drug Class, By Disease Type, By Route of Administration, By End Use - Global Forecast, 2026-2035

Based on the drug class, the global market is segmented into anticoagulants, antiplatelet drugs, and thrombolytic drugs. The anticoagulants segment dominated the market with 85% market share and was valued at USD 40.2 billion in 2025. The anticoagulants segment is further classified into direct oral anticoagulants, heparin, vitamin K antagonists, and injectable DTIs.
 

• The major factor for the dominance of this segment is its widespread use across both prophylactic and therapeutic settings, particularly in the management of atrial fibrillation, venous thromboembolism, stroke prevention, and post-surgical thromboprophylaxis, supported by strong clinical guidelines and extensive physician familiarity.
   
• In addition, the growing adoption of direct oral anticoagulants due to their predictable efficacy, convenient dosing, and reduced monitoring requirements further reinforces the leadership of the anticoagulants segment.
   
• On the other hand, the antiplatelet drugs segment is expected to grow at a 7.8% CAGR driven by the rise in atherosclerotic cardiovascular diseases and the extensive use of antiplatelet therapy as a means of secondary prevention in myocardial infarction and ischemic stroke.
   
• The increasing demand for dual antiplatelet therapy has been significantly fueled by the growing number of percutaneous coronary interventions (PCI) and stent placements, thereby contributing to segmental growth.
   

Based on the disease type, the global thrombosis drugs market is classified into venous thromboembolism, arterial thrombosis, atrial fibrillation, cerebrovascular disorders, and other disease types. The venous thromboembolism segment dominated the market in 2025 and is estimated to reach USD 40.3 billion by 2035. The venous thromboembolism segment is further sub-segmented into deep vein thrombosis and pulmonary embolism.
 

• The growth of this segment can be attributed to the rising incidence of deep vein thrombosis and pulmonary embolism globally, driven by aging populations, increasing prevalence of cancer and obesity, prolonged hospitalizations, and higher volumes of surgical procedures that elevate VTE risk.
   
• Growing awareness and implementation of thromboprophylaxis guidelines in hospitals and outpatient settings are leading to higher diagnosis and treatment rates.
   
• Further, improved diagnostic techniques and expanding use of long-term anticoagulation therapy for secondary prevention are supporting segment growth.
   
• On the other hand, the atrial fibrillation (AF) segment is anticipated to witness growth at a CAGR of 7.8% over the forecast period, driven by the rising prevalence of atrial fibrillation, an aging population, and improved diagnosis and treatment options.
   
• For example, the absolute prevalence of AF has nearly doubled in the last 30 years, from 22.2 million in 1990 to 52.5 million in 2021. As a result, the growing patient pool and expanding treatment adoption are expected to strongly support sustained market growth for atrial fibrillation therapies over the forecast period.
   

Learn more about the key segments shaping this market

Download Free PDF

Based on the route of administration, the global thrombosis drugs market is segmented into oral, parenteral, and topical. The oral segment dominated the market with a market share of 79.7% in 2025 due to its ease of administration, high patient compliance, and suitability for long-term outpatient therapy, particularly in chronic conditions such as atrial fibrillation and venous thromboembolism.
 

• The growing preference for novel oral anticoagulants (NOACs) over traditional injectable or vitamin K antagonist therapies contributes to the significant growth of the oral segment.
   
• Additionally, factors such as fixed dosing, minimal dietary restrictions, and a lower risk of drug-drug interactions have made oral formulations more convenient for both patients and healthcare providers.
   
• Further, the increasing availability of generic oral anticoagulants has improved affordability and access, further boosting adoption in developed and emerging markets.
   
• The parenteral segment, on the other hand, is anticipated to witness growth at a CAGR of 7.1% in the coming years, because of the continued reliance on injectable anticoagulants in acute and critical care settings, including hospitals and intensive care units. Their rapid onset of action, precise dose control, and preference in perioperative care, emergency management, and in high-risk patient populations are key factors driving sustained growth.
   

Based on the end use, the global thrombosis drugs market is classified into hospitals, ambulatory surgical centers, and other end users. The hospitals segment held the largest market size with a revenue of USD 25.5 billion in 2025.
 

• This dominance is fueled by the growing number of surgical procedures, including orthopedic, cardiovascular, and cancer-related surgeries, which carry a high risk of venous thromboembolism (VTE) and necessitate prophylactic or therapeutic use of thrombosis drugs.
   
• Hospitals also cater to a large population of critically ill and hospitalized patients who require immediate anticoagulation, such as those with acute coronary syndromes, pulmonary embolism, or atrial fibrillation.
   
• Furthermore, hospitals benefit from advanced diagnostic tools, patient monitoring systems, and trained staff, allowing for the safe administration of complex therapies like injectable heparins or titrated oral anticoagulants.
   
• Additionally, hospitals often act as centers for clinical trials and the introduction of new anticoagulant drugs, providing early access to innovative therapies and reinforcing their central role in the market.
   

Looking for region specific data?

Download Free PDF

North America Thrombosis Drugs Market
 

The North America market dominated the global market with a market share of 59.5% in 2025.
 

• The region boasts a comprehensive healthcare infrastructure that includes technologically advanced hospitals, specialized cardiac and surgical centers, and a broad availability of both oral and parenteral anticoagulants.
   
• The significant prevalence of cardiovascular diseases, atrial fibrillation, and venous thromboembolism, especially in the aged population, has resulted in enormous demand for thrombosis management therapies.
   
• Additionally, early adoption of novel oral anticoagulants (NOACs), robust reimbursement policies, and widespread awareness of thromboprophylaxis guidelines among healthcare providers have further reinforced North America’s leadership in the market.
   

The U.S. thrombosis drugs market was valued at USD 22.7 billion and USD 23.5 billion in 2022 and 2023, respectively. The market size reached USD 25.4 billion in 2025, growing from USD 24.1 billion in 2024.
 

• This growth is largely driven by the high prevalence of thrombotic conditions, including atrial fibrillation, venous thromboembolism, and stroke. According to the Centers for Disease Control and Prevention (CDC), a stroke occurs every 40 seconds in the U.S., and approximately every 3 minutes and 11 seconds, someone dies from a stroke, highlighting the significant health burden posed by thromboembolic events.
   
• Stroke remains a leading cause of mortality and long-term disability, emphasizing the critical need for effective anticoagulant and antithrombotic therapies.
   
• Strong adoption of novel oral anticoagulants (NOACs), increasing awareness of thromboprophylaxis, advanced healthcare infrastructure, and favorable reimbursement policies have further accelerated the market growth, making the U.S. the largest contributor to the North American market.
   

Europe Thrombosis Drugs Market
 

Europe market accounted for USD 9.4 billion in 2025 and is anticipated to show lucrative growth over the forecast period.
 

• This growth is primarily driven by the region’s aging population, which is more prone to thrombotic disorders, and the prevalence of cardiovascular diseases (CVDs), the primary cause of death in Europe, which is responsible for more than 3.9 million deaths annually, as per the European Heart Network.
   
• Strong public healthcare systems and widespread access to advanced diagnostic and treatment facilities support the timely management of thromboembolic conditions, further boosting market demand.
   

Germany dominates the Europe thrombosis drugs market, showcasing strong growth potential.
 

• Germany leads the Europe market, supported by its advanced healthcare infrastructure, high standard of medical care, and widespread access to both oral and parenteral anticoagulants.
   
• The country has a significant aging population, which is more susceptible to thrombotic disorders such as atrial fibrillation, venous thromboembolism, and stroke. Additionally, Germany’s strong emphasis on cardiovascular disease prevention, early diagnosis, and adherence to clinical guidelines for thromboprophylaxis drives higher utilization of thrombosis drugs.
   

Asia Pacific Thrombosis Drugs Market
 

The Asia Pacific market is anticipated to grow at the highest CAGR of 8.1% during the analysis timeframe, driven by the rising prevalence of cardiovascular diseases and stroke, particularly in countries such as China, India, Japan, and South Korea.
 

• As per the World Health Organization (WHO), stroke ranks as the second leading cause of death in Southeast Asia, affecting millions annually and highlighting the urgent need for effective thrombotic care.
   
• Population aging is another key driver; according to the World Bank, Japan leads globally with over 29% of its population aged 65 and older, increasing the demand for thrombosis prevention and long-term management.
   
• Additionally, improving healthcare infrastructure, greater access to advanced diagnostic and therapeutic options, growing awareness of thromboembolic risks, and the adoption of novel oral anticoagulants (NOACs) in clinical practice are supporting rapid market expansion across the region.
   

China thrombosis drugs market is estimated to grow with a significant CAGR in the Asia Pacific market.
 

• The country is experiencing a rising prevalence of cardiovascular diseases, atrial fibrillation, and venous thromboembolism, largely driven by urbanization, lifestyle changes, and an aging population.
   
• Additionally, the increasing awareness of stroke and thromboembolic risk among healthcare providers and patients is boosting demand for preventive and therapeutic anticoagulant therapies.
   
• Moreover, the expanding healthcare infrastructure, including more hospitals, specialized cardiac centers, and improved diagnostic facilities, supports timely treatment and wider adoption of thrombosis drugs.
   

Latin American Thrombosis Drugs Market
 

Brazil leads the Latin American market, exhibiting remarkable growth during the analysis period due to its large patient population with a high prevalence of cardiovascular diseases, including atrial fibrillation, venous thromboembolism, and stroke.
 

• The country’s expanding middle-class population, rising healthcare expenditure, and improved insurance coverage are facilitating greater access to anticoagulant therapies.
   
• Additionally, government-led public health programs promoting early detection and management of thrombotic conditions, combined with growing awareness among physicians and patients about stroke prevention, are driving higher prescription rates.
   

Middle East and Africa Thrombosis Drugs Market
 

Saudi Arabia market is expected to experience substantial growth in the Middle East and Africa market.
 

• The market growth is driven by the rapid modernization of its healthcare system, including investment in advanced hospital infrastructure and specialized cardiovascular care centers. The rising prevalence of risk factors such as diabetes, obesity, and sedentary lifestyles is increasing thrombotic disease incidence.
   
• Additionally, supportive regulatory frameworks, government initiatives to expand access to innovative therapies, and growing awareness of thromboprophylaxis among healthcare providers are driving the adoption of thrombosis drugs across the country.
  
   

Thrombosis Drugs Market Share

Leading companies such as Bristol-Myers Squibb, Bayer, Daiichi Sankyo, Johnson & Johnson, and Sanofi account for approximately 58.7% of the market share. Innovations in oral therapies, subcutaneous formulations, and long acting injectables are driving therapeutic advancement and patient adherence.
 

Additionally, partnerships with academic institutions and licensing agreements for novel pipeline candidates are stimulating progress, particularly in targeting factor-specific clotting mechanisms. Many companies are also increasing investments in research and development to develop safer agents with reduced bleeding risks. Efforts to expand access in developing regions and improve treatment affordability further highlight the market’s shift toward global inclusivity and personalized care.
 

Thrombosis Drugs Market Companies

Prominent players operating in the thrombosis drugs industry are as mentioned below:
 

• Aspen Pharmacare
• AstraZeneca
• Bayer
• Boehringer Ingelheim
• Bristol-Myers Squibb
• Chiesi Farmaceutici
• Daiichi Sankyo
• Dr. Reddy’s Laboratories
• Johnson & Johnson
• Karma Pharmatech
• Lupin
• Microbix Biosystems
• Novartis
• Pfizer
• Sanofi
• Teva Pharmaceuticals
  
   
• Bristol-Myers Squibb

The company accounted for approximately 29.7% and has established a strong presence in the market through its portfolio of anticoagulants, including both oral and injectable therapies. The company has focused on innovation in novel oral anticoagulants (NOACs) and combination therapies, addressing critical needs in atrial fibrillation, venous thromboembolism, and post-surgical thromboprophylaxis.
 

• Boehringer Ingelheim

The company made a significant impact with its development and continued evolution of direct thrombin inhibitors, supporting a shift toward safer and more convenient alternatives to traditional therapies. In early 2024, Boehringer Ingelheim expanded the indications for its flagship oral anticoagulant to include broader patient populations, supported by compelling long-term outcome data. This move strengthened its relevance in stroke prevention and management.
 

• Bayer

Bayer has carved out a strong position in the thrombosis drug market through its flagship direct oral anticoagulant. With a focus on Factor Xa inhibition, Bayer has advanced the standard of care in conditions such as venous thromboembolism, atrial fibrillation, and stroke prevention.
 

Thrombosis Drugs Industry News

• In May 2025, Microbix Biosystems and Sequel Pharma executed an agreement with a contract development and manufacturing organization (CDMO) for the production of Kinlytic drug product. This collaboration aims to reintroduce Kinlytic to the U.S. market, initially targeting the catheter clearance indication. The partnership is fully funded by Sequel Pharma. It helped the company to strengthen its thrombolytic portfolio.
   
• In February 2025, Novartis completed the acquisition of Anthos Therapeutics, a clinical-stage biopharmaceutical firm focused on anticoagulation. The deal included the return of abelacimab, a late-stage Factor XI inhibitor initially licensed from Novartis. It strengthened the company’s position in thrombosis drug development and cardiovascular research.
   
• In February 2025, Boehringer Ingelheim launched a fast-acting stroke medication containing Tenecteplase 25 mg in the UAE, administered as a single IV bolus over 5-10 seconds, significantly reducing treatment time for acute ischemic stroke. This helped the company strengthen its footprint in the Middle East stroke treatment market.
   
• In March 2024, Bristol Myers Squibb and Janssen conducted 3 concurrent phase 3 trials under the Librexia program to evaluate milvexian, a Factor XIa inhibitor, for ischemic stroke, acute coronary syndrome, and atrial fibrillation. Milvexian showed potential in both monotherapy and combination therapy with reduced bleeding risk and no monitoring requirements. This strengthened BMS’s research and development pipeline in the anticoagulant segment.